Pharmacological Targeting of Glucagon and Glucagon-Like Peptide 1 Receptors Has Different Effects on Energy State and Glucose Homeostasis in Diet-Induced Obese Mice

  title={Pharmacological Targeting of Glucagon and Glucagon-Like Peptide 1 Receptors Has Different Effects on Energy State and Glucose Homeostasis in Diet-Induced Obese Mice},
  author={Wei Gu and David J Lloyd and Narumol Chinookswong and Renee Komorowski and Glenn Sivits and Melissa Graham and Katherine A. Winters and Hai Yan and L{\'a}szl{\'o} G. Boros and Richard A. Lindberg and Murielle M. V{\'e}niant},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={70 - 81}
  • W. Gu, D. Lloyd, M. Véniant
  • Published 1 July 2011
  • Biology, Medicine, Chemistry
  • Journal of Pharmacology and Experimental Therapeutics
Pharmacologic contributions of directly agonizing glucagon-like peptide 1 (GLP-1) receptor or antagonizing glucagon receptor (GCGR) on energy state and glucose homeostasis were assessed in diet-induced obese (DIO) mice. Metabolic rate and respiratory quotient (RQ), hyperglycemic clamp, stable isotope-based dynamic metabolic profiling (SiDMAP) studies of 13C-labeled glucose during glucose tolerance test (GTT) and gene expression were assessed in cohorts of DIO mice after a single administration… 

Figures and Tables from this paper

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes

The elevated circulating GLP-1 level by GCGR mAb is mainly due to intestinal L-cell proliferation and GLP -1 production, which may be mediated via GLp-1R/PKA signaling pathways.

Human Monoclonal Antibodies against Glucagon Receptor Improve Glucose Homeostasis by Suppression of Hepatic Glucose Output in Diet-Induced Obese Mice

A novel human monoclonal GCGR antibody, NPB112, effectively lowered the glucose level in diabetic animal models with mild and reversible hyperglucagonemia and may be a promising therapeutic modality for the treatment of type 2 diabetes.

The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin

Chronic treatment of obese mice with OXM and OXMQ3E demonstrated that OXM exhibits superior weight loss and lipid‐lowering efficacy, and antihyperglycemic activity that is comparable to the corresponding GLP1R‐selective agonist.

Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor Signaling

In spite of the increase in iBAT thermogenesis induced by GLP-1R activation in WT mice, Glp1r−/− mice exhibit a normal response to cold exposure, demonstrating that endogenous GLP 1R signaling is not essential for appropriate thermogenic response after cold exposure.

GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice

It is proposed that by increasing basal energy expenditure, GLP-1(32-36)amide might be a useful treatment for human obesity and associated metabolic disorders.

Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model.

Coagonist of GLP-1 and glucagon receptors improved lipid metabolism in liver of dyslipidemic hamsters, and the improved FGF21 sensitivity could be the mechanism of hypolipidemic action of the coagonists of GLp-1/glucagon receptors.

Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys.

The GCGR-blocking antibody REGN1193 normalizes blood glucose in diabetic mice and monkeys but does not produce hypoglycemia in normoglycemic monkeys, and provides a potential therapeutic modality for diabetes mellitus and acute hyperglycemic conditions.



Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.

Data show that pancreatic GLP-1 is a significant contributor to the glucose-lowering effects observed in response to GCGR antagonist treatment, and generated a monoclonal antibody that specifically antagonizes the human GLp-1R.

Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

It is indicated that GLP-1, in addition to its well known effect of stimulating insulin secretion, may improve insulin responsiveness by promoting fatty acid synthesis in adipose cells and possibly modulating insulin signaling in other insulin sensitive tissues.

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

It is shown that brain GLP-1 controlled whole-body glucose fate during hyperglycemic conditions and inhibited muscle glucose utilization and increased insulin secretion to favor hepatic glycogen stores, preparing efficiently for the next fasting state.

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

It is demonstrated that GLP-1 decreases feelings of hunger and reduces energy intake in obese humans and one possible mechanism for this finding might be an increased satiety primarily mediated by gastric vagal afferent signals.

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

Preclinical studies indicate that when full GLP-1 agonism is augmented with an appropriate degree of glucagon receptor activation, body fat reduction can be substantially enhanced without any overt adverse effects.

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.

GLP-1 is able to reverse some of the known defects that arise in the beta cell of the pancreas of Wistar rats, not only by increasing insulin secretion but also by inducing significant changes at the molecular level.

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

The results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.

Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not

Comparisons ofabolic effects of the glucagon-like peptide-1 analog liraglutide and the dipeptidyl peptidase-IV inhibitor vildagliptin in rats made obese by supplementary candy feeding indirectly suggested that both drugs increased insulin sensitivity.

Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.

Findings illustrate that DPP-4 inhibition modulates glucose homeostasis through pathways distinct from those used by GLP-1R agonists in mice.

Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible α-Cell Hyperplasia and Hyperglucagonemia

It is demonstrated that a 5-week treatment of diet-induced obese mice with mAb effectively normalized nonfasting blood glucose without inducing hypoglycemia or other undesirable metabolic perturbations, and further support the concept that long-term inhibition of GCGR signaling by a mAb could be an effective approach for controlling diabetic hyperglycemia.